Goodbye Columbus! New NRDOs forego discovery

Nature Biotechnology

Volumn 22, Issue 9, 2004, Pages 1087-1092

  Thiel, Karl A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DISCOVERY; SUSTAINABLE BUSINESS;

BIOTECHNOLOGY; DRUG DOSAGE; INDUSTRY; INVESTMENTS; SUSTAINABLE DEVELOPMENT;

DRUG PRODUCTS;

ALOXIL; GLUCOPAHGE; HIRULOG; MEMANTINE; METFORMIN; MODAFINIL; PALONOSETRON; RAMIPRIL; THALIDOMIDE; UNCLASSIFIED DRUG;

COMMERCIAL PHENOMENA; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; INVESTMENT; LICENSING; PRIORITY JOURNAL; SHORT SURVEY; SUSTAINABLE DEVELOPMENT; TREATMENT INDICATION;

DRUG DESIGN; DRUG INDUSTRY; ENTREPRENEURSHIP; INTERNATIONALITY; LICENSURE; MODELS, ECONOMIC; OWNERSHIP; PHARMACEUTICAL PREPARATIONS; RESEARCH;

EID: 4444345450     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0904-1087     Document Type: Short Survey

References (2)

1. Sampaio, E.P. et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699-703 (1991).
2. Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571 (1999).